The growth of Viagra and its impact on the drug landscape presents a intricate question for investors. While the initial sales data were impressive, the intellectual property has lapsed, leading to a wave of generic alternatives that are chipping away at profit. In addition, the market is facing issues related to demographic trends and shifting hea